FY2025 EPS Estimate for CRISPR Therapeutics Cut by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at William Blair reduced their FY2025 earnings per share estimates for shares of CRISPR Therapeutics in a report released on Monday, November 10th. William Blair analyst S. Corwin now anticipates that the company will post earnings per share of ($5.07) for the year, down from their prior forecast of ($4.78). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. William Blair also issued estimates for CRISPR Therapeutics’ Q4 2025 earnings at ($1.03) EPS, Q1 2026 earnings at ($0.90) EPS, Q2 2026 earnings at ($0.92) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.82) EPS and FY2026 earnings at ($3.46) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.17) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.15. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%.The company had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $8.74 million.

A number of other research analysts have also issued reports on CRSP. Wedbush cut their price target on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 5th. Bank of America upped their price target on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Zacks Research raised shares of CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Royal Bank Of Canada boosted their price target on shares of CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a research report on Tuesday. Finally, Needham & Company LLC decreased their price target on CRISPR Therapeutics from $81.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday. Eleven analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and an average price target of $67.84.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP traded down $1.06 on Thursday, reaching $51.13. 391,451 shares of the stock traded hands, compared to its average volume of 2,549,014. The company has a fifty day moving average price of $63.02 and a 200-day moving average price of $53.44. CRISPR Therapeutics has a 12 month low of $30.04 and a 12 month high of $78.48. The company has a market cap of $4.87 billion, a price-to-earnings ratio of -9.17 and a beta of 1.89.

Insider Activity

In other news, CEO Samarth Kulkarni sold 50,895 shares of the stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the transaction, the chief executive officer directly owned 254,201 shares in the company, valued at $17,262,789.91. This represents a 16.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel James R. Kasinger sold 1,076 shares of the firm’s stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the transaction, the general counsel directly owned 83,402 shares in the company, valued at approximately $5,554,573.20. This represents a 1.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 56,213 shares of company stock valued at $3,810,458 in the last three months. 4.30% of the stock is currently owned by corporate insiders.

Institutional Trading of CRISPR Therapeutics

A number of hedge funds have recently bought and sold shares of the company. ARK Investment Management LLC grew its stake in CRISPR Therapeutics by 13.3% in the first quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company’s stock valued at $345,929,000 after purchasing an additional 1,192,336 shares in the last quarter. State Street Corp increased its holdings in CRISPR Therapeutics by 35.6% in the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock valued at $159,082,000 after buying an additional 859,334 shares during the period. Orbis Allan Gray Ltd grew its holdings in shares of CRISPR Therapeutics by 76.9% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after purchasing an additional 1,201,600 shares during the last quarter. Vanguard Group Inc. increased its position in shares of CRISPR Therapeutics by 2.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,364,645 shares of the company’s stock valued at $153,253,000 after buying an additional 66,556 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of CRISPR Therapeutics by 98.1% in the second quarter. Geode Capital Management LLC now owns 2,071,883 shares of the company’s stock valued at $100,789,000 after purchasing an additional 1,025,979 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.